Yoshitaka Nabeshima

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

Hideyuki Hyogo, Susumu Tazuma, Koji Arihiro et al. · Metabolism · 2008 · 208 citations

Medicine, Pharmacology, Pharmacotherapy +12

Elevated levels of serum advanced glycation end products in patients with non‐alcoholic steatohepatitis

Hideyuki Hyogo, Sho‐ichi Yamagishi, Keiko Iwamoto et al. · Journal of Gastroenterology and Hepatology · 2007 · 191 citations

Medicine, Endocrinology, Aging +10

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

Yuki Kimura, Hideyuki Hyogo, Sho‐ichi Yamagishi et al. · Journal of Gastroenterology · 2010 · 160 citations

Veterinary Medicine, Pharmacology, Pharmacotherapy +12

Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis

Yoshitaka Nabeshima, Susumu Tazuma, Keishi Kanno et al. · Biochemical and Biophysical Research Communications · 2006 · 86 citations

Life Sciences, Molecular Biology, Pharmacology +15

Deletion of angiotensin II type I receptor reduces hepatic steatosis

Yoshitaka Nabeshima, Susumu Tazuma, Keishi Kanno et al. · Journal of Hepatology · 2009 · 58 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12